ISPE has released the results of its 2013-2014 International Board of Directors election. The new board will be responsible for the governance and strategic direction of ISPE and will assume their roles at the 2013 ISPE Annual Meeting, November 3 to 6, in Washington, DC.
“ISPE is in the midst of significant growth and transitioning to guide and support the pharmaceutical industry as it addresses issues such as increasing regulatory and pricing pressures, global markets, supply chains and manufacturing innovation,” said ISPE president and chief executive officer Nancy Berg. “I am confident that the incoming international board of directors will build upon the work of previous boards and the Society’s past success and lead ISPE in its mission to support the pharmaceutical industry’s efforts to provide safe, high quality medications for patients around the world.”
Damian Greene, global network strategy lead, Global Manufacturing and Supply, Zoetis, will serve as chair. Andy Skibo, regional vice president, Biologics-Supply, MedImmune/AstraZeneca, will serve as vice chair. Joseph Famulare, vice president – Global Compliance and External Collaboration, Genentech, was named treasurer. Mike Arnold, R.Ph., business process owner for investigational products and senior director of Strategic Partnerships, Global Clinical Supply Chain, Pfizer, will serve as secretary.
Re-elected directors include: James A. Breen, Jr., PE, LEED AP, vice president, Worldwide Engineering and Technical Operations, Supply Chain Group, Johnson & Johnson, and Tim Howard, CPIP, PE, vice president of Global Operations and Company Officer, Commissioning Agents, Inc. Directors Jennifer Lauria Clark, CPIP, Jim Durkin, and Gordon Leichter, Ph.D., elected in 2012 to serve a two-year term, will continue their service on the board.
New directors include: Mark Fitch, senior vice president of Global Operations, Impax Laboratories, Inc. Thomas Hartman, vice president, GMP Operations, Biopharm CMC, GlaxoSmithKline, Robert Matje, PE, CPIP, senior director of Engineering, Endo, Christopher Reid, chief executive officer and principal consultant and owner, Integrity Solutions Ltd., and Fran Zipp (Sakers), group executive vice president and head of Quality Operations, Teva.